Hydreight Technologies: Strong 2026 Growth Guidance, Operating Leverage, and Discounted Valuation Support Buy Rating

Analyst Allen Klee from Maxim Group reiterated a Buy rating on Hydreight Technologies Inc and increased the price target to C$9.50 from C$8.50.

Allen Klee has given his Buy rating due to a combination of factors tied to Hydreight Technologies’ strong growth outlook, improving profitability, and attractive valuation. Management’s 2026 guidance for both revenue and adjusted EBITDA is materially ahead of prior forecasts and consensus, implying more than triple-digit revenue growth and a nearly tenfold increase in EBITDA year over year. Klee highlights that this guidance is framed as a conservative baseline, leaving room for upside from potential acquisitions, new geographies, or additional commercial partnerships, while fixed costs are expected to remain relatively stable. He also points to the recently launched direct-to-consumer platform as the primary growth engine, complemented by continued expansion of the nurse network and pharmaceutical sales.

In his view, Hydreight’s balance sheet is adequately capitalized to support its organic growth plans, with the existing cash position and the recent private placement providing sufficient liquidity, though further capital could be needed for M&A. Klee notes that, despite the robust growth and margin profile implied by 2026 guidance, the stock is currently trading at a modest EV/EBITDA multiple relative to peers and its own growth trajectory. His 12-month price target increase reflects applying a higher multiple to the updated 2026 EBITDA outlook, suggesting meaningful upside from current trading levels. Taken together, the combination of strong projected financial performance, operating leverage, solid funding for growth, and a discounted valuation underpins his Buy recommendation on Hydreight Technologies Inc.